Stryker European Holdings I LLC

Intendis Gmbh

Other

Merck Patent Gmbh

Stryker European Operations Holdings LLC

Leukocare Ag

Pharmatech Gmbh

Hartwig Steckel

Torben Christian Sörensen

Philip Procter

Nils Reimers

Mirjam Lilja

Maren Kuhli

Karin Hoffmann

Regina Scherliess

Jan Henrik Sörensen

Michael Wolf

Jens Altrichter

Markus Weigandt

Martin Scholz

Andrea Hanefeld

Kristina Kemter

Matthias Schroeder

Peter Walden

Percy Knolle

Andrea Diedrich

Renato Brito Baleeiro

Ken Welch

Jan Soerensen

Jan Henrik Soerensen

Torben SÖRENSEN

Biomaterials, in particular bone foams, a process for preparing such materials as well as an applicator for applying the biomaterials directly to the patient's application site, and the use of a composition comprising water, a surfactant and a propellant in the preparation of a bone foam for the preparation of a calcium phosphate foam wherein the foam is obtainable by the mixture of at least two phases, a first phase comprising water and optionally a propellant, a second phase comprising one or more sources for calcium and/or phosphate, and wherein the foaming is performed during the mixture of the at least two phases to provide an improved calcium phosphate foam, process for the preparation of a calcium phosphate foam, use of a composition, solid state structure, calcium phosphate cement foam and bone foam applicator.

Polymeric bone foam composition and method

A method of manufacturing an implant for use in a surgical procedure, a corresponding implant and the use thereof during the incorporation of a substance is presented. Specifically anodized and blasted titanium implant substrates are provided with a hydroxyapatite (HA) coating for incorporating for example a therapeutic agent. In particular, an anodizing procedure by an electrolytic process in an alkaline liquid is carried out. Moreover, blasting of the anodized titanium implant substrate is carried out by the presented method. The HA coating can be in the range of 1 to 5 &#x3bc;m, particularly in the range of 1 to 3 &#x3bc;m. A local delivery of the active pharmaceutical ingredient is achieved by the implant of the present invention. Moreover, the implant allows for the removal of the implant without damaging surrounding tissue or a bone. Moreover, the HA coating is provided to the substrate such that enhanced fixation as measured by pull-out force is achieved whilst having a relatively low removal torque. The HA coating and drug incorporation may be carried out sequentially but also co-precipitation approach can be used.

Method of manufacturing an implant for use in a surgical procedure

The present invention relates to a method for producing stabilised vaccines, the method comprising: (a) mixing antigens with a solution comprising: (i) chitosan; (ii) at least three different amino acids and/or at least one dipeptide or tripeptide; and (iii) a sugar; and (b) drying the mixture obtained in (a).

Method for the production of stabile vaccines

The present invention is directed to nanoparticles comprising chitosan and an antigen, whereby the chitosan has a degree of deacetylation of about 90% and a molecular weight from 5 kDa to 80 kDa, to microparticles containing such nanoparticles as well as to a process for preparation of such particles. The particles are usable for vaccination.

Antigen-loaded chitosan nanoparticles for immunotherapy

A method for co-precipitating a therapeutic agent into a hydroxyapatite coated surface includes the steps of providing a surface and applying a hydroxyapatite seed layer on the surface. The hydroxyapatite seed layered surface is contacted with a solution including the therapeutic agent and a co-precipitated therapeutic agent, hydroxyapatite layer is formed on the coated surface to uniformly distribute the therapeutic agent in the layer. Further, an implant having sustained therapeutic agent delivery includes a base and an hydroxyapatite seed layer disposed on a surface of the base. A co-precipitated hydroxyapatite coating is disposed on the seed layer. The coating includes a therapeutic agent, wherein the therapeutic agent is provided in a solution of therapeutic agent.

Co-precipitation of a therapeutic agent into hydroxyapatite coatings

The present patent application is related to a hydrogel composition which is essentially free of active drugs for the manufacture of a product for the treatment of dermatological disorders, especially perioral dermatitis, acne or seborrheic dermatitis.

Hydrogel composition for the treatment of dermatological disorders

A method for loading a hydroxyapatite coated implant with a therapeutic agent including the steps of providing an implant and applying a hydroxyapatite coating on a surface of the implant. The hydroxyapatite coated implant is contacted with a solution including the therapeutic agent. The hydroxyapatite coated implant and solution is heated to temperature of about 60&#xb0; C. to about 100&#xb0; C. Pressure is applied to the hydroxyapatite coated implant and solution from about 2 bar to about 10 bar, to load the hydroxyapatite coated implant with the therapeutic agent. An implant made according to the method has sustained therapeutic agent delivery and includes a base and a biomimetic hydroxyapatite coating disposed on a surface thereof.

Method for drug loading hydroxyapatite coated implant surfaces

The present invention provides a formulation which contains a poorly water soluble pharmaceutically active compound at a concentration of 50 mg per 100 g formulation or above. The solubility is achieved by a mixture of solvents as described herein. Moreover the formulation as described herein may be used as a base formulation to generate a cream, an ointment, a spray, a foam or an oleogel.

Pharmaceutical composition for topical application of poorly soluble compounds

Growing community of inventors

Kiel, Germany

Hartwig Steckel